Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: In vitro and in vivo studies

Journal of Immunology

Volumn 162, Issue 3, 1999, Pages 1707-1716

  Delgado, Mario ^a,b   Munoz Elias, Ernesto J ^a   Gomariz, Rosa P ^b   Ganea, Doina ^a  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NEUROPEPTIDE; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOREGULATION; INFLAMMATION; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADENYLATE CYCLASE; ANIMALS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; ENZYME ACTIVATION; INTERLEUKIN-10; KINETICS; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; NEUROPEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RNA, MESSENGER; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0033083302     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Laskin, D. L., and K. J. Pendino. 1995. Macrophages and inflammatory mediators in tissue injury. Annu. Rev. Pharmacol. Toxicol. 35:655.
2. 2 regulates macrophage-derived tumor necrosis factor gene expression. J. Biol. Chem. 263:5380.
3. Trepicchio, W., M. Bozza, G. Pedneault, and A. Dorner. 1996. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J. Immunol. 157: 3627.
4. Fiorentino, D. F., A. Zlotnik, T. R. Mossman, M. Howard, and A. O'Garra. 1991. Interleukin-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:3815.
5. Tsunawaki, S., M. Sporn, A. Ding, and C. F. Nathan. 1988. Deactivation of macrophages by transforming growth factor β. Nature 334:260.
6. Muchamuel, T., S. Menon, P. Pisacane, M. C. Howard, and D. A. Cockayne. 1997. IL-13 protects mice from LPS-induced lethal endotoxemia. J. Immunol. 158:2898.
7. Ganea, D. 1996. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv. Neuroimmunol. 6:61.
8. De la Fuente, M., M. Delgado, and R. P. Gomariz. 1996. VIP modulation of immune cell functions. Adv. Neuroimmunol. 6:75.
9. Martinez, C. M. Delgado, D. Pozo, J. Leceta, J. R. Calvo, D. Ganea, and R. P. Gomariz. 1998. Vasoactive intestinal peptide and pituitary adenylale cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J. Leukocyte Biol. 63:591.
10. Hernanz, A., E. Tato, M. De la Fuente, E. De Miguel, and F. Amalich. 1996. Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1β, interleukin-6 and tumor necrosis factor-α production by whole blood cells from healthy young and old subjects. J. Neuroimmunol. 71:25.
11. Dewit, D., P. Gourlet, Z. Amraoui, P. Vertongen, F. Willems, P. Robberecht, and M. Goldman. 1998. The vasoactive intestinal peptide analogue R025-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. Immunol. Lett. 60:57.
12. Delgado, M., C. Martinez, D. Pozo, J. R. Calvo, J. Leceta, D. Ganea, and R. P. Gomariz. 1999. VIP and PACAP protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J. Immunol. In press.
13. Harmar, A. J., A. Arimura, I. Gozes, L. Journot, M. Laburthe, J. R. Pisegna, S. R. Rawlings, P. Robberecht, S. I. Said, S. P. Sreedharan, et al. 1999. Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP). Pharmacol. Rev. 50:625.
14. Rawlings, S. R., and M. Hezareh. 1996. Pituitary adenylate cyclase activating polypeptide and PACAP/vasoactive intestinal polypeptidc receptors: actions on the anterior pituitary gland. Endocr. Rev. 17:4.
15. Segura, J. J., J. M. Guerrero, R. Goberna, and J. R. Calvo. 1991. Characterization of functional receptors for vasoactive intestinal peptide (VIP) in rat peritoneal macrophages. Regul. Pept. 33:133.
16. Delgado, M., D. Pozo, C. Martinez, E. Garrido, J. Leceta, J. R. Calvo, and R. P. Gomariz. 1996. Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages. Regul. Pept. 62:161.
17. Pozo, D., M. Delgado, C. Martinez, R. P. Gomariz, J. M. Guerrero, and J. R. Calvo. 1997. Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptor in rat peritoneal macrophages. Biochim. Biophys. Acta 1359:250.
18. Florentino, D. F., M. W. Bond, and T. R. Mosmann. 1989. Two types of mouse T helper cell. IV. TH2 clones secrete a factor that inhibits cytokine production by TH1 clones. J. Exp. Med. 170:2081.
19. de Waal Malefyt, R., J. Haanen, H. Spits, M. G. Roncarolo, A. te Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, and J. E. de Vries. 1991. IL-10 and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II histocompatibility complex expression. J. Exp. Med. 174:915.
20. de Waal Malefyt, R., J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries. 1991. Inlerleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:1209.
21. Barsig, J., S. Kusters, K. Vogt, H. D. Volk, G. Tiegs, and A. Wendel. 1995. Lipopolysaccharide-induced interleukin-10 in mice: role of endogenous tumor necrosis factor-α. Eur. J. Immunol. 25:2888.
22. Bogdan, C., Y. Vodovotz, and C. Nathan. 1991. Macrophage deactivation by interleukin 10. J. Exp. Med. 174:1549.
23. D'Andrea, A., M. Aste-Amezaga, N. M. Valiante, X. Ma, M. Kubin, and G. Trinchieri. 1993. Interleukin 10 inhibits human IFNγ production by suppressing natural killer cell stimulatory factor IL-12 synthesis in accessory cells. J. Exp. Med. 178:1041.
24. Wang, P., P. Wu, M. I. Siegel, R. W. Egan, and M. M. Bilah. 1994. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J. Immunol. 153:811.
25. Aste-Amezaga, M., X. Ma, A. Sartoiri, and G. Trinchieri. 1998. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J. Immunol. 160: 5936.
26. Martinez, C., M. Delgado, R. P. Gomariz, D. Ganea. 1996. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J. Immunol. 156:4128.
27. Kim, J. M., C. I. Brannan, N. G. Copeland, N. A. Jenkins, T. A. Khan, and K. W. Moore. 1992. Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J. Immunol. 148:3618.
28. O'Garra, A., R. Chang, N. Go, R. Hastings, G. Haughton, and M. Howard. 1992. Ly-1 B (B-1) cells are the main source of B-cell derived interleukin-10. Eur. J. Immunol. 22:711.
29. Gourlet, P., A. Vandermeers, P. Vertongen, J. Ratche, P. De Neef, J. Cnudde, M. Waelbroeck, and P. Robberecht. Development of high affinity selective VIP1 receptor agonists. Peptides 18:1539-1545.
30. Gourlet, P., P. Vertongen, A. Vandermeers, M. C. Vandermmers-Piret, J. Rathe, P. De Neef, M. Waelbroeck, and P. Robberecht. 1997. The long-acting vasoactive intestinal polypeplide agonist RO25-1553 is highly selective of the VIP2 receptor subclass. Peptides 18:403.
31. Moro, O., and E. A. Lemer. 1996. Maxadilan, the vasodilator peptide from sand flies, is a specific pituitary adenylate cyclase activating peptide type 1 receptor agonist. J. Biol. Chem. 271:966.
32. Gourlet, P., M. C. Vandermeers-Piret, J. Rathe, P. De Neef, and P. Robberecht. 1995. Fragments of the pituitary adenylatc cyclase-activating polypeptide discriminate between type I and II recombinant receptors. Eur. J. Pharmacol. 287:7.
33. Gourlet, P., P. De Neef, J. Cnudde, M. Waelbroeck, and P. Robberecht. 1997. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 18:1555.
34. Kobayashi, E., H. Nakno, M. Morimoto, and T. Tamaoki. 1989. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 159:548.
35. Chijiwa, T., A. Mishima, M. Hagiwara, M. Sano, K. Hayashi, T. Inoue, K. Naito, T. Toshioka, and H. Hidaka. 1990. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase. N-[2-(p-bromociannamylamino)ethyl]-5-isoquinoleinsulfonamide (H89), of PC12D pheochromocytoma cells. J. Biol. Chem. 265:5267.
36. Boige, N., B. Aminaroff, A. Munk, and M. Laburthe. 1984. Forskolin stimulates adenylate cyclase in human colonic crypts: interaction with VIP. Eur. J. Pharmacol. 101:111.
37. Platzer, C., C. Meisel, K. Vogt, M. Platzer, and H. D. Volk. 1995. Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugs. Int. Immunol 7:517.
38. Strassmann, G., V. Patil-Koota, F. Finkelman, M. Fong, and T. Kambayashi. 1995. Evidence for the involvement of interleukin-10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J. Exp. Med. 180: 2365.
39. Arai, T., K. Hiromatsu, N. Kobayashi, M. Takano, H. Ishida, Y. Nimura, and Y. Yoshikai. 1995. IL-10 is involved in the protective effect of dibutyryl cyclic adenosine monophosphate on endotoxin-induced inflammatory liver injury. J. Immunol. 155:5743.
40. Kambayashi, T., C. O. Jacob, D. Zhou, N. Mazurek, M. Fong, and G. Strassmann. 1995. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J. Immunol. 155:4909.
41. Bellinger, D. L., D. Lorton, S. Brouxhon, S. Felten, and D. L. Felten. 1996. The significance of vasoactive intestinal peptide (VIP) in immunomodulation. Adv. Neuroimmunol. 6:5.
42. Said, S. I. 1985. Vasoactive intestinal peptide. In: Airways Smooth Muscle: Peptide Receptors, Ion Channels, and Signal Transduction. D. Raenburn and M. A. Giembycz, eds. Birkhauser Verlag Basel, Switzerland, p. 87.
43. Van Snick, J. 1990. Interleukin 6: an overview. Annu. Rev. Immunol. 8:253.
44. Vassali, P. 1992. The pathophysiology of tumor necrosis factor. Annu. Rev. Immunol. 10:411.
45. Gourlet, P., J.-P. Vilardaga, P. De Neef, M. Waelbroeck, A. Vandermeers, and P. Robberecht. 1996. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides 17:825.
46. O'Donnell, M., R. J. Garippa, N. C. O'Neill, D. R. Bolin, and J. M. Cottrell, 1991. Structure-activity studies of vasoactive intestinal polypeptide. J. Biol. Chem. 266:6389.
47. Delgado, M., E. J. Munoz-Elias, Y. Kan, I. Gozes, M. Fridkin, D. E. Brenneman, R. P. Gomariz, and D. Ganea. 1998. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit TNFα transcriptional activation by regulating NF-κB and CREB/c-Jun. J. Biol. Chem. 273:31427.
48. Wang, H.-Y., Z Xin., H. Tang, and D. Ganea. 1996. Vasoactive intestinal peptide inhibits IL-4 production in murine T cells by a post-transcriptional mechanism. J. Immunol. 156:3243.
49. Muller, A., B. Lutz-Bucher, P. Kienlen-Campard, B. Koch, and J. P. Loeffler. 1998. Continuous activation of pituitary adenylate cyclase-activating polypeptide receptors elicits antipodal effects on cyclic AMP and inositol phospholipid signaling pathways in CATH.a cells: role of protein synthesis and protein kinases. J. Neurochem. 70:1431.
50. Aoki, Y., Y. Iwasaki, M. Katahira, Y. Oiso, and H. Saito. 1997. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II. Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide. Endocrinology 138:1930.
51. Schomerus, C., E. Maronde, E. Laedtke, and H. W. Korf. 1996. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) induce phosphorylation of the transcription factor CREB in subpopulations of rat pinealocytes: immunocytochemical and immunochemical evidence. Cell. Tissue Res. 286:305.
52. Hsueh, Y.-P., and M.-Z. Lai. 1995. C-Jun N-terminal kinase but not mitogen-activated protein kinase is sensitive to cAMP inhibition in T lymphocytes. J. Biol. Chem. 270:18094.
53. Howard, M., T. Muchamuel, S. Andrade, and S. Menon. 1993. Interleukin 10 protects mice from lethal endotoxemia. J. Exp. Med. 177:1205.
54. Wang, R., Q. Fang, L. Zhang, L. Radvany, A. Sharma, N. Noben-Trauth, G. B. Mills, and Y. Shi. 1997. CD28 ligation prevents bacterial toxin-induced septic shock in mice by inducing IL-10 expression. J. Immunol. 158:2856.
55. van der Poll, T., P M. Jansen, W. J. Montegut, C. C. Braxton, S. E. Calvano, S, A. Stackpole, S. R. Smith, S. W. Swanson, C. E. Hack, S. F. Lowry, et al. 1997. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. J. Immunol. 158:1971.
56. Tumpey, T. M., V. M. Elner, S. Chen, J. E. Oakes, and R. N. Lausch. 1994. Interleukin 10 treatment can suppress stromal keratitis induced by herpes simplex virus type 1. J. Immunol. 153:2258.
57. Mulligan, M. S., M. L. Jones, A. A. Vaporciyan, M. C. Howard, and P. A. Wood. 1993. Protective effects of IL-4, and IL-10 against immune complex induced lung injury. J. Immunol. 151:5666.
58. Schreiber, S., T. Heinig, H. G. Thiele, and A. Raedler. 1995. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108:1434.
59. Pearse, A. G. E., J. M. Polak, and S. R. Bloom. 1977. The newer gut hormone: cellular sources, physiology, pathology, and clinical aspects. Gastroenterology 72:746.
60. Dey, R. D., W. A. Shannon, and S. I. Said. 1981. Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cats, and human subjects. Cell Tissue Res. 220:231.
61. Grider, J. R., and J.-G. Jin. 1993. Vasoactive intestinal peptide release and L-citrulline production from isolated ganglia of the myenteric plexus: evidence for regulation of vasoactive intestinal peptide release by nitric oxide. Neuroscience 54:521.
62. Allescher, H. D., M. Kurjak, A. Huber, P. Trudrung, and V. Schusdziarra. 1996. Regulation of VIP release from rat enteric nerve terminals: evidence for a stimulatory effect of NO. Am. J. Physiol. 271:G568.
63. Delgodo, M., D. Pozo, C. Martinez, J. Leceta, J. R. Calvo, D. Genea, and R. P. Gomariz. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-α production by macrophages: in vitro and in vivo studies. J. Immunol. 162, In press.